TR201904662T4 - Anti-fxı antikorları ve kullanma yöntemleri. - Google Patents

Anti-fxı antikorları ve kullanma yöntemleri. Download PDF

Info

Publication number
TR201904662T4
TR201904662T4 TR2019/04662T TR201904662T TR201904662T4 TR 201904662 T4 TR201904662 T4 TR 201904662T4 TR 2019/04662 T TR2019/04662 T TR 2019/04662T TR 201904662 T TR201904662 T TR 201904662T TR 201904662 T4 TR201904662 T4 TR 201904662T4
Authority
TR
Turkey
Prior art keywords
fxi
monoclonal antibodies
antibodies
patent application
fxiia
Prior art date
Application number
TR2019/04662T
Other languages
English (en)
Inventor
Gruber Andras
I Tucker Erik
Gailani David
Original Assignee
Gruber Andras
Gailani David
I Tucker Erik
Univ Oregon Health & Science
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruber Andras, Gailani David, I Tucker Erik, Univ Oregon Health & Science, Univ Vanderbilt filed Critical Gruber Andras
Publication of TR201904662T4 publication Critical patent/TR201904662T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Bu patent başvurusunda, faktör XI (fXI) için spesifik olan ve faktör XIIa (fXIIa) ile fXI aktivasyonunu önleyen monoklonal antikorlar açıklanmaktadır. Bu monoklonal antikorlar, test edilen tüm memeli türlerini bağlama kabiliyeti bulunan evrensel fXI antikorlarıdırlar. Anti-fXI monoklonal antikorları, memeli plazmalarında pıhtılaşma süresini uzatırlar. Ayrıca, bu patent başvurusunda açıklanan fXI monoklonal antikorlarının uygulanması, trombozun hayvan modellerinde, trombozun hemostazı değiştirmeden inhibe edilmesiyle sonuçlanmaktadır. Dolayısıyla, bu patent başvurusunda, fXI için spesifik olan ve fXIIa ile fXI aktivasyonunu bloke eden monoklonal antikorlar, bu tür antikorları içeren bileşimler ve immünokonjügatlar ve ayrıca, bunları kullanma yöntemleri açıklanmaktadır.
TR2019/04662T 2008-12-18 2009-12-18 Anti-fxı antikorları ve kullanma yöntemleri. TR201904662T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13859008P 2008-12-18 2008-12-18

Publications (1)

Publication Number Publication Date
TR201904662T4 true TR201904662T4 (tr) 2019-05-21

Family

ID=42317079

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04662T TR201904662T4 (tr) 2008-12-18 2009-12-18 Anti-fxı antikorları ve kullanma yöntemleri.

Country Status (15)

Country Link
US (3) US8388959B2 (tr)
EP (1) EP2373691B1 (tr)
AU (1) AU2009335643B2 (tr)
CA (1) CA2747519C (tr)
CY (1) CY1121562T1 (tr)
DK (1) DK2373691T3 (tr)
ES (1) ES2720594T3 (tr)
HR (1) HRP20190605T1 (tr)
HU (1) HUE042940T2 (tr)
LT (1) LT2373691T (tr)
PL (1) PL2373691T3 (tr)
PT (1) PT2373691T (tr)
SI (1) SI2373691T1 (tr)
TR (1) TR201904662T4 (tr)
WO (1) WO2010080623A2 (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160046728A1 (en) * 2007-10-31 2016-02-18 Bioxodes Sa Identification and molecular characterisation of proteins, expressed in the ixodes ricinus salivary glands
AU2009335643B2 (en) * 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
CN102600471A (zh) * 2012-02-15 2012-07-25 中国人民解放军军事医学科学院微生物流行病研究所 一种败血症治疗的靶点
US9783614B2 (en) * 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
JOP20160131B1 (ar) * 2015-06-26 2022-03-14 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3325516B1 (en) 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
US10053515B2 (en) * 2016-01-22 2018-08-21 Merck Sharp & Dohme Corp. Anti-coagulation factor XI antibodies
KR102448456B1 (ko) * 2016-03-23 2022-09-28 프로틱스 비브이 인자 xi의 활성 부위에 대한 모노클로날 항체 및 이의 용도
EP3455636B1 (en) * 2016-05-13 2023-08-23 The Scripps Research Institute Compositions and methods for anti-thrombotic and hemostatic therapies
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EA201892716A1 (ru) * 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Антитела к фактору свертывания xi
AU2017329645A1 (en) * 2016-09-20 2019-04-04 Aronora Inc. Novel antibodies against factor XI and uses thereof
CN118320078A (zh) * 2016-12-23 2024-07-12 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
KR102616666B1 (ko) * 2016-12-23 2023-12-27 노파르티스 아게 인자 xi 항체 및 사용 방법
CN108409863B (zh) 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
EP3713965A1 (en) 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
CN113227150B (zh) * 2018-08-09 2023-07-28 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US12703762B2 (en) 2018-12-18 2026-08-11 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
AU2020211905A1 (en) * 2019-01-21 2021-08-05 Aronora Inc. Novel humanized antibodies against factor XI having anti-thrombotic and anti-inflammatory effects and uses thereof
EP3957652A4 (en) 2019-04-16 2023-06-21 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-fxi/fxia antibody and use thereof
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
BR112022026533A2 (pt) * 2020-07-02 2023-01-17 Beijing Tuo Jie Biopharmaceutical Co Ltd Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo
CN122124233A (zh) * 2020-07-03 2026-06-02 苏州康宁杰瑞生物科技有限公司 凝血因子xi (fxi)结合蛋白
CN118414168A (zh) 2021-10-22 2024-07-30 里珍纳龙药品有限公司 因子xi a2结构域结合抗体和其使用方法
US20240409667A1 (en) * 2023-06-07 2024-12-12 Oregon Health & Science University Inhibition of contact pathway activation for the treatment of neuroinflammation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US8574849B2 (en) * 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
CA2705851C (en) * 2007-11-21 2016-11-01 Oregon Health & Science University Anti-factor xi monoclonal antibodies and methods of use thereof
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
CA2743864A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
AU2009335643B2 (en) * 2008-12-18 2014-05-29 Oregon Health & Science University Anti-fXI antibodies and methods of use
UA107112C2 (uk) 2010-05-27 2014-11-25 Мерк Шарп Енд Доме Корп. Активатори розчинної гуанілатциклази
CA2803688A1 (en) 2010-06-25 2011-12-29 Bayer Intellectual Property Gmbh Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
US20140171434A1 (en) 2011-01-11 2014-06-19 Bayer Pharma Aktiengessellschaft Substituted imidazopyridines and imidazopyridazines and the use thereof
WO2012143510A1 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
BR112014005110A2 (pt) 2011-09-02 2017-04-18 Bayer Ip Gmbh pirimidinas aneladas substituídas e utilização das mesmas
US9783614B2 (en) 2012-05-10 2017-10-10 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof

Also Published As

Publication number Publication date
AU2009335643A1 (en) 2011-07-07
AU2009335643B2 (en) 2014-05-29
HRP20190605T1 (hr) 2019-05-31
US20130129745A1 (en) 2013-05-23
US20150093395A1 (en) 2015-04-02
CA2747519A1 (en) 2010-07-15
WO2010080623A2 (en) 2010-07-15
WO2010080623A3 (en) 2010-11-18
US8388959B2 (en) 2013-03-05
EP2373691A2 (en) 2011-10-12
US9637550B2 (en) 2017-05-02
DK2373691T3 (en) 2019-04-15
US20110250207A1 (en) 2011-10-13
EP2373691A4 (en) 2012-10-31
HUE042940T2 (hu) 2019-07-29
LT2373691T (lt) 2019-05-27
SI2373691T1 (sl) 2019-05-31
ES2720594T3 (es) 2019-07-23
PL2373691T3 (pl) 2019-07-31
CA2747519C (en) 2019-04-02
CY1121562T1 (el) 2020-05-29
EP2373691B1 (en) 2019-01-23
US8940883B2 (en) 2015-01-27
PT2373691T (pt) 2019-05-08

Similar Documents

Publication Publication Date Title
WO2010080623A3 (en) Anti-fxi antibodies and methods of use
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1121536T1 (el) Ανθρωπινα αντισωματα εναντι-αλφα-συνουκλεϊνης
PH12019501126A1 (en) Bispecific antibodies binding to coagulation factor ix and ciagulation factor x
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
EA201100300A1 (ru) Композиции и способы, предназначенные для направленного воздействия антител на белок c5 системы комплемента
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
MX2018005512A (es) Agentes de union de esclerostina.
NO20084878L (no) Humanisert C-kit antistoff
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
DOP2012000089A (es) Anticuerpos monoclonales
CL2008003561A1 (es) Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias.
GT201000088A (es) 2 -fluoro-2´desoxitetrahidrouridinas como inhibidores de citidina desaminasa
BR112021012667A2 (pt) Proteínas de ligação anti-pd-1 e métodos de uso destas
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
EP3716757A4 (en) WEED CONTROL COMPOSITIONS, KITS AND PROCEDURES
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
EA201490823A1 (ru) Агенты, реверсирующие действие антикоагулянтов
NO20084320L (no) Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов